Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioVie Inc.
  6. Summary
    BIVI   US09074F2074

BIOVIE INC.

(BIVI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
15.51(c) 15.65(c) 15.52(c) 15.7(c) 15.07(c) Last
32 563 10 669 26 484 20 500 7 293 Volume
+3.40% +0.90% -0.83% +1.16% -4.01% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -89,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,10x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -181 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,93x
Yield 2022 -
Capitalization 337 M 337 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 3
Free-Float 11,4%
More Financials
Company
BioVie Inc. clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing... 
More about the company
All news about BIOVIE INC.
07/22BIOVIE : to Present Rationale for use of NE3107 for the Treatment of Alzheimer's..
AQ
07/16Basis for BioVie's Phase 3 Clinical Trial of NE3107 in the Treatment of Alzhe..
GL
07/16BioVie to Launch a Pivotal Phase 3 Trial in Alzheimer’s This Summer to Assess..
CI
06/29Development of BioVie's NE3107 Asset Featured by the American Diabetes Associ..
GL
06/28BIOVIE : Added to Russell Microcap« Index
AQ
06/25BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Rep..
GL
06/24BIOVIE : Enrolls First Patient in Phase 2b Trial of BIV201 to Treat Ascites
MT
06/24BIOVIE : Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for ..
AQ
06/24BioVie Inc. Announces First Patient Enrolled in BIV201 Phase 2b Clinical Tria..
CI
06/23BIOVIE : Obtains FDA Guidance for Phase 3 Clinical Study of BIV201 in Hepatorena..
MT
06/23BIOVIE : Receives FDA Guidance for Phase 3 Clinical Trial of BIV201 in HRS-AKI
AQ
06/23BioVie Inc. Receives FDA Guidance for Phase 3 Clinical Trial of Biv201 in HRS..
CI
06/17BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Rep..
GL
06/11BIOVIE : Announces Closing of Acquisition of BioPharma Assets from Privately Hel..
PU
06/11BIOVIE INC. : Entry into a Material Definitive Agreement, Completion of Acquisit..
AQ
More news
News in other languages on BIOVIE INC.

- No features available -

More news
Analyst Recommendations on BIOVIE INC.
More recommendations
Chart BIOVIE INC.
Duration : Period :
BioVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 15,07 $
Average target price 50,00 $
Spread / Average Target 232%
EPS Revisions
Managers and Directors
Cuong Viet Do President, Chief Executive Officer & Director
Joanne Wendy Kim Chief Financial Officer & Secretary
Terren S. Peizer Chairman
Penelope Markham Chief Scientific Officer
Patrick Yeramian Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOVIE INC.-12.99%387
GILEAD SCIENCES, INC.18.01%85 134
WUXI APPTEC CO., LTD.32.49%71 226
REGENERON PHARMACEUTICALS19.60%57 013
BIONTECH SE251.15%55 555
VERTEX PHARMACEUTICALS-15.83%50 308